help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on September 4, 2007
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2007-1213
A more recent version of this article appeared on November 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
92/11/4271    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bogazzi, F.
Right arrow Articles by Martino, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bogazzi, F.
Right arrow Articles by Martino, E.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL
Related Collections
Right arrow Cardiovascular Endocrinology
Right arrow Endocrine Oncology
Right arrow Metabolism
Right arrow Neuroendocrinology and Pituitary

Submitted on May 31, 2007
Accepted on August 29, 2007

Risk Factors for Development of Coronary Heart Disease in Patients with Acromegaly: A 5-Year Prospective Study

Fausto Bogazzi*, Luigi Battolla, Cheti Spinelli, Giuseppe Rossi, Silvia Gavioli, Vitantonio Di Bello, Chiara Cosci, Chiara Sardella, Duccio Volterrani, Enrica Talini, Pasquale Pepe, Fabio Falaschi, Giuliano Mariani, and Enio Martino

Department of Endocrinology and Metabolism (F.B., S.G., C.C., C.S., E.M.), University of Pisa, 56124 Pisa, Italy; Second Radiodiagnostic Unit (L.B., C.Sp., F.F), Azienda Ospedaliera Pisana, 56124 Pisa, Italy, Unit of Epidemiology and Biostatistics (G.R., P.P.), Institute of Clinical Physiology, National Research Council (C.N.R.), 56100 Pisa, Italy, Cardio-Thoracic Department (V.D.B., E.T.), University of Pisa, 56124 Pisa, Italy, Regional Center of Nuclear Medicine (D.V., G.M.), 56100 Pisa, Italy

* To whom correspondence should be addressed. E-mail: f.bogazzi{at}endoc.med.unipi.it or fbogazzi@hotmail.com.

Background Data on coronary heart disease (CHD) are scanty and matter of argument in acromegalic patients.

Objective To evaluate risk factors for development of CHD and the occurrence of cardiac events in acromegalic patients during a 5-year prospective study.

Design Ten-year likelihood for CHD development was estimated by the Framingham scoring system(FS); patients were stratified as having low(FS<10), intermediate(≥10FS <20) or high(FS≥20) risk. Coronary artery calcium content was measured using the Agatston score(AS) in all patients; those with positive AS were submitted to myocardial SPECT; cardiac events were recorded during a 5-year follow-up period.

Patients Fifty-two consecutive patients (31 women, mean age52±11yr) with controlled or uncontrolled acromegaly followed prospectively for 5 years.

Results Thirty-seven patients(71%) had low, 14 patients(27%) intermediate and 1 patient(2%) high CHD risk. CHD risk was unrelated to acromegaly activity, or the estimated duration of disease. Among patients with FS<10%, 24 had AS=0, 8 AS≥1 and <100, and 5 AS≥100 and <300, respectively. Among patients with ≥10FS<20%, 8 had AS=0, 4 had 1AS<100, 1 had ≥100AS<300 and 2 had AS≥300; a patient of the latter group, having AS≥400, increased his CHD risk from 11% to ≥20%. FS or AS did not differ in patients with controlled or uncontrolled acromegaly (p=0.981). All patients with positive AS had no SPECT perfusion defects. During the 5-year follow-up period no patient developed ischemic cardiac events.

Conclusions CHD risk in acromegalic patients, predicted by FS as in non-acromegalic subjects, is low; AS might have adjunctive role only in a subset of patients. However, most patients have systemic complications of acromegaly, which participate in the assessment of global CHD risk.


Key words: Acromegaly • heart • GH • IGF-1 • coronary heart disease • calcium score







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society